|Research and Markets: Global Hyperoxaluria Pipeline Insights Report 2015|
Hyperoxaluria Pipeline Insights provides the in-depth analysis of the pipeline assets across the Hyperoxaluria. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in ...
Digital Journal - Fri, 26 Jun 2015 03:07
|Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the ...|
Hyperoxaluria is excessive urinary excretion of oxalate, a condition resulting from either hyperabsorption of dietary oxalate or the overproduction of oxalate in the body due to one of several known genetic defects. Hyperoxaluria, if left untreated ...
Business Wire (press release) - Wed, 18 Mar 2015 05:22
|FDA Grants Orphan Drug Designation for DCR-PH1, Dicerna's Investigational ...|
... of RNA interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCR-PH1, the company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1).
Business Wire (press release) - Thu, 23 Apr 2015 13:48
|OxThera Initiates Clinical Trial in Primary Hyperoxaluria|
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for ...
PR Newswire (press release) - Wed, 08 Jan 2014 00:26
|Allena Pharmaceuticals Appoints Louis Brenner, M.D. as Chief Operating Officer|
“Allena is rapidly advancing a novel treatment approach for patients with hyperoxaluria. There are extremely limited options for patients with this difficult condition,” said Dr. Brenner. “The company has demonstrated encouraging clinical results to ...
Business Wire (press release) - Thu, 16 Apr 2015 05:22
|Allena Pharmaceuticals Secures $25 Million Series B Financing|
“The positive response and level of interest we have received from investors is a great reflection of our seasoned management team, the market opportunity and the unmet need that ALLN-177 meets in the treatment of hyperoxaluria,” said Alexey Margolin, ...
Business Wire (press release) - Thu, 04 Dec 2014 04:00
|Biotech partners at Allena fund a march toward PhIII with $25M venture round|
FierceBiotech - Thu, 04 Dec 2014 05:53
|Poster Highlights Rapid and Durable Effect of DCR-PH1 in Mouse Model of PH1|
WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, presented data from its preclinical program in primary hyperoxaluria type 1 (PH1) in a poster session at the ...
Business Wire (press release) - Tue, 14 Oct 2014 14:22
|Holden girl awaits kidney and liver transplant|
Holden – 11-year old Teodora Bastug is currently on the list to receive a new kidney and a new liver after being diagnosed with “hyperoxaluria,” four years ago. Hyperoxaluria is a rare condition in which there is too much oxalate produced in the body ...
Community Advocate - Sat, 02 May 2015 09:52